ÂÜÀòÂÒÂ×

Patricia Hurter is an accomplished pharmaceutical executive with extensive experience in drug development and regulatory affairs. Currently serving as a board member for Synlogic, Inc. since February 2019, Patricia has also been the CEO of Lyndra Therapeutics from September 2019 to December 2023, leading innovations in long-acting oral drug delivery. Prior to this, Patricia held several senior roles at Vertex Pharmaceuticals from June 2004 to April 2019, including Senior Vice President of Pharmaceutical & Preclinical Sciences and Interim Head of Global Regulatory Affairs, overseeing significant regulatory submissions and drug development processes. Earlier career positions include Director of Formulation Development at Merck and Group Leader at Union Camp. Patricia holds a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology and a Master's in Mechanical Engineering from West Virginia University, complemented by undergraduate qualifications in Chemical Engineering from the University of KwaZulu-Natal.